DETERMINING SPECIFIC THYROID TRANSCRIPTS
IN PERIPHERAL BLOOD:
A SINGLE CENTER STUDY EXPERIENCE Makazlieva T, Eftimov A, Vaskova O, Tripunoski T,
Miladinova D, Risteski S, Jovanovic H, Jakovski Z
Tanja Makazlieva and Aleksandar Eftimov contributed equally to this study
and are considered first coauthors. *Corresponding Author: Tanja Makazlieva, Ph.D., Institute of Pathophysiology and Nuclear Medicine,
Medical Faculty, Mother Teresa Street, No. 17, 1000, Skopje, Republic of Macedonia.
Mobile: +389-75-313-665. E-mail: tmakazlieva@medf.ukim.edu.mk or tmakazlieva@gmail.com page: 13 download article in pdf format
|
Abstract
Thyroid carcinoma (TC) comprises a spectrum of different
tumors with a wide range of biological behavior and
prognosis. The techniques based on the latest trends in molecular
biology may have application in diagnosis of metastatic
TC. The aim of this study was to apply and analyze
mRNA expression in peripheral blood of thyrotropin receptor
[thyroid stimulating hormone receptor (TSHR-mRNA)]
gene and thyroglobulin (Tg-mRNA) gene using 2–ΔΔCt method
in differentiated TC patients and healthy individuals.
Fifty-seven subjects were included in the study, consisting
of 40 patients with TC and 17 healthy volunteers as a control
group. Total RNA was isolated from peripheral blood and
used for two-step reverse transcriptase-polymerase chain reaction
(PCR). Real-time PCR was performed with appropriate
primers. Relative quantification using the 2–ΔΔCt method
was applied. Thyroid carcinoma patients with metastatic
disease or loco-regional relapse expressed TSHR-mRNA by
a 8.57-fold higher level than healthy controls. Thyroid carcinoma
patients with biochemical relapse expressed TSHRmRNA
by a 14.17-fold higher level than healthy controls,
while expression of Tg-mRNA was 6.6-fold higher in TC
patients with metastatic disease and loco-regional relapse
than healthy controls and 8.34-fold higher level compared
with TC patients with excellent response to treatment. Our
preliminary study showed that the TSHR gene expression
might have more useful application as a biomarker compared
to detection of Tg gene expression.
|
|
|
|
|
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|